Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Synthelabo Looking Long (In Dosing), Deep (In U.S. Market) For Ambien

Executive Summary

Sanofi-Synthelabo is considering extending the half-life of its lead product Ambien (zolpidem) in an effort to differentiate the hypnotic agent from the recently approved Wyeth-Ayerst competitor drug Sonata, Sanofi-Synthelabo Chief Operating Officer Herve Guerin indicated at Sept. 2 meeting in London.

You may also be interested in...



Sanofi-Synthelabo/Bristol Plan Avapro Heart Failure Program

Sanofi-Synthelabo and co-marketing partner Bristol-Myers Squibb are discussing Phase III protocols in cardiac insufficiency for the angiotensin II inhibitor Avapro (irbesartan), Sanofi-Synthelabo COO Herve Guerin told an analysts meeting in London Sept. 2.

Sanofi-Synthelabo/Bristol Plan Avapro Heart Failure Program

Sanofi-Synthelabo and co-marketing partner Bristol-Myers Squibb are discussing Phase III protocols in cardiac insufficiency for the angiotensin II inhibitor Avapro (irbesartan), Sanofi-Synthelabo COO Herve Guerin told an analysts meeting in London Sept. 2.

Wyeth Sonata Short-Term Psychomotor Symptoms Allows Mid-Night Dosing

The short-term psychomotor effects of Wyeth-Ayerst's insomnia drug Sonata (zaleplon) allow late night dosing without significant lingering effects the following day.

UsernamePublicRestriction

Register

PS034796

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel